



Ana Marcu

Contact

Ana Marcu

Publications (8)

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neeffjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. *Sci Immunol* 2022; 7:eabn9644.

Kubiniok P, Marcu A, Bichmann L, Kuchenbecker L, Schuster H, Hamelin D, Duquette J, Kovalchik K, Wessling L, Kohlbacher O, Rammensee H, Neidert M, Sirois I, Caron E. Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues. *iScience* 2022; 25:103768.

Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neeffjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. *Oncoimmunology* 2021; 10:2006893.

Nelde A, Rammensee H, Aulitzky W, Illerhaus G, Denzlinger C, Neidert M, Bauer J, Marcu A, Heitmann J, Roerden M, Salih H, Bilich T, Maringer Y, Walz J. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. *Front Immunol* 2021; 12:705974.

Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunother Cancer* 2021; 9

Bilich T, Stevanovic S, Rammensee H, Neidert M, Schuhmacher J, Lübke M, Marcu A, Besemer B, Weisel K, Salih H, Roerden M, Walz S, Bauer J, Nelde A, Walz J. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. *Blood Cancer J* 2020; 10:24.

Bilich T, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper J, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanovic S, Brümmendorf T, Schemionek M, Rieth J, Nelde A, Bichmann L, Roerden M, Salih H, Kowalewski D, Schuster H, Tsou C, Marcu A, Neidert M, Lübke M, Walz J. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. *Blood* 2018; 133:550-565.

Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018; 135:923-938.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch